Clinically, KRAS mutations are associated with poor prognosis, resistance to anti-EGFR monoclonal antibodies (like cetuximab and panitumumab), and limited therapeutic options, making this a challenging subset of CRC to treat [3,6,8]. This evidence concerns the gene EGFR and colorectal carcinoma.